Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2025-12-26 @ 2:31 AM
Study NCT ID:
NCT06832202
Status:
RECRUITING
Last Update Posted:
2025-06-15
First Post:
2025-02-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
Sponsor:
Shanghai Henlius Biotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-04-16
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-12
First Submit QC Date:
None
Study First Post Date:
2025-02-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-12
Last Update Post Date:
2025-06-15
Last Update Post Date Type:
ACTUAL